GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » C-Rad AB (LTS:0R44) » Definitions » EV-to-EBITDA

C-Rad AB (LTS:0R44) EV-to-EBITDA : 14.08 (As of Sep. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is C-Rad AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, C-Rad AB's enterprise value is kr1,079.7 Mil. C-Rad AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was kr76.7 Mil. Therefore, C-Rad AB's EV-to-EBITDA for today is 14.08.

The historical rank and industry rank for C-Rad AB's EV-to-EBITDA or its related term are showing as below:

LTS:0R44' s EV-to-EBITDA Range Over the Past 10 Years
Min: -219.83   Med: 25.53   Max: 1223.65
Current: 14.08

During the past 13 years, the highest EV-to-EBITDA of C-Rad AB was 1223.65. The lowest was -219.83. And the median was 25.53.

LTS:0R44's EV-to-EBITDA is ranked better than
52.28% of 482 companies
in the Medical Devices & Instruments industry
Industry Median: 14.59 vs LTS:0R44: 14.08

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-22), C-Rad AB's stock price is kr36.30. C-Rad AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was kr1.570. Therefore, C-Rad AB's PE Ratio for today is 23.12.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


C-Rad AB EV-to-EBITDA Historical Data

The historical data trend for C-Rad AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C-Rad AB EV-to-EBITDA Chart

C-Rad AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.32 58.20 38.67 36.51 24.34

C-Rad AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.13 19.23 24.34 19.67 17.32

Competitive Comparison of C-Rad AB's EV-to-EBITDA

For the Medical Devices subindustry, C-Rad AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C-Rad AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where C-Rad AB's EV-to-EBITDA falls into.



C-Rad AB EV-to-EBITDA Calculation

C-Rad AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1079.676/76.658
=14.08

C-Rad AB's current Enterprise Value is kr1,079.7 Mil.
C-Rad AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr76.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C-Rad AB  (LTS:0R44) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

C-Rad AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=36.30/1.570
=23.12

C-Rad AB's share price for today is kr36.30.
C-Rad AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


C-Rad AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of C-Rad AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


C-Rad AB Business Description

Traded in Other Exchanges
Address
Sjukhusvägen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. The operating segments of the group are the Positioning segment which includes development and sales of products in the field of patient positioning during radiotherapy, including catalyst, sentinel, and HIT lasers; and the Imaging segment which includes the development of imaging devices and detectors for cancer treatments and dosimetry. It generates maximum revenue from the Positioning segment. The firm sells its products in Sweden and internationally.

C-Rad AB Headlines

No Headlines